US 12,491,385 B2
Targeting SARS-CoV-2 viral-immune interaction for COVID-19 therapy
Jun Wang, New York, NY (US); Qiao Lu, New York, NY (US); Jia Liu, New York, NY (US); Chao Bai Huang, San Leandro, CA (US); Jianbo Dong, Santa Clara, CA (US); and Yue Liu, Foster City, CA (US)
Assigned to New York University, New York, NY (US)
Filed by NEW YORK UNIVERSITY, New York, NY (US); and AB STUDIO INC., Hayward, CA (US)
Filed on Sep. 24, 2021, as Appl. No. 17/484,483.
Claims priority of provisional application 63/106,507, filed on Oct. 28, 2020.
Claims priority of provisional application 63/083,060, filed on Sep. 24, 2020.
Prior Publication US 2022/0089695 A1, Mar. 24, 2022
Int. Cl. A61P 31/14 (2006.01); C07K 16/10 (2006.01); C07K 16/28 (2006.01); C07K 16/40 (2006.01); C12N 15/79 (2006.01); G01N 33/569 (2006.01)
CPC C07K 16/40 (2013.01) [A61P 31/14 (2018.01); C07K 16/1003 (2023.08); C07K 16/28 (2013.01); C07K 16/2851 (2013.01); C12N 15/79 (2013.01); G01N 33/56983 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2319/30 (2013.01); C12N 2800/10 (2013.01); G01N 2333/165 (2013.01)] 14 Claims
 
1. An inhibitor of the binding of SARS-CoV-2 S protein to one or more SARS-CoV-2 S protein interacting partner, wherein the inhibitor is a bispecific antibody comprising the CDR sequences of SEQ ID NO: 57-SEQ ID NO: 59 and the CDR sequences of SEQ ID NO: 93-SEQ ID NO: 95.